{"id":4144,"date":"2025-04-28T13:00:10","date_gmt":"2025-04-28T13:00:10","guid":{"rendered":"https:\/\/www.sygnaturediscovery.com\/poster\/dna-damage-response-biomarkers-preclinical-oncology\/"},"modified":"2026-01-22T14:17:38","modified_gmt":"2026-01-22T14:17:38","slug":"dna-damage-response-biomarkers-preclinical-oncology","status":"publish","type":"poster","link":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/dna-damage-response-biomarkers-preclinical-oncology\/","title":{"rendered":"Early biomarker dynamics are associated with treatment efficacy in a preclinical model of radiotherapy combines with a DNA damage response agent"},"content":{"rendered":"<p>Sygnature Discovery&rsquo;s <a href=\"https:\/\/www.sygnaturediscovery.com\/therapeutic-areas\/oncology-and-immuno-oncology\/\">oncology<\/a> team presents new data exploring DNA damage response (DDR) signalling and biomarker dynamics in A549 preclinical models. This work highlights how DDR inhibitors combined with radiotherapy can drive enhances efficacy and support mechanism-of-action studies in preclinical oncology.<\/p>\n<h3>Study Highlights<\/h3>\n<ul>\n<li>Early biomarker profiling supports mechanistic insight<\/li>\n<li>Combination therapy improves in vivo efficacy<\/li>\n<li>Transcriptomic changes reveal treatment-specific effects<\/li>\n<\/ul>\n<h3>Advancing Preclinical Oncology Research<\/h3>\n<p>These findings support the use of DNA damage response-targeted strategies in combination with radiotherapy, highlighting the role of early biomarker profiling and gene expression analysis in guiding treatment development. The A549 model proved highly responsive to DDR modulation, offering a valuable tool for translation research.<\/p>\n<h2>Discovery our Oncology Expertise<\/h2>\n<p>Sygnature Discovery provides integrated support for preclinical oncology research, from <a href=\"https:\/\/www.sygnaturediscovery.com\/drug-discovery\/bioscience\/\">in vitro pharmacology<\/a> and <a href=\"https:\/\/www.sygnaturediscovery.com\/drug-discovery\/in-vivo-pharmacology-and-in-vivo-testing\/\">efficacy models<\/a> to <a href=\"https:\/\/www.sygnaturediscovery.com\/drug-discovery\/bioscience\/biomarker-discovery-validation-and-development\/\">biomarker discovery<\/a> and transcriptomic analysis. Our experiences team can help you explore combination strategies and accelerate oncology drug discovery.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":2883,"template":"","category":[685,751,738],"class_list":["post-4144","poster","type-poster","status-publish","has-post-thumbnail","hentry","category-in-vivo-pharmacology","category-oncology","category-oncology-models"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DNA Damage Response Biomarkers in Preclinical Oncology<\/title>\n<meta name=\"description\" content=\"New A549 data showing DDR inhibition with radiotherapy improves in vivo efficacy, with biomarker and transcriptomic profiling of the response. Learn more.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/dna-damage-response-biomarkers-preclinical-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DNA Damage Response Biomarkers in Preclinical Oncology\" \/>\n<meta property=\"og:description\" content=\"New A549 data showing DDR inhibition with radiotherapy improves in vivo efficacy, with biomarker and transcriptomic profiling of the response. Learn more.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/dna-damage-response-biomarkers-preclinical-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Sygnature\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T14:17:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/DNA-damage-response-biomarkers-preclinical-ongology-feature-e1744811293329.png\" \/>\n\t<meta property=\"og:image:width\" content=\"888\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/dna-damage-response-biomarkers-preclinical-oncology\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/dna-damage-response-biomarkers-preclinical-oncology\\\/\",\"name\":\"DNA Damage Response Biomarkers in Preclinical Oncology\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/dna-damage-response-biomarkers-preclinical-oncology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/dna-damage-response-biomarkers-preclinical-oncology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/DNA-damage-response-biomarkers-preclinical-ongology-feature-e1744811293329.png\",\"datePublished\":\"2025-04-28T13:00:10+00:00\",\"dateModified\":\"2026-01-22T14:17:38+00:00\",\"description\":\"New A549 data showing DDR inhibition with radiotherapy improves in vivo efficacy, with biomarker and transcriptomic profiling of the response. Learn more.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/dna-damage-response-biomarkers-preclinical-oncology\\\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/dna-damage-response-biomarkers-preclinical-oncology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/dna-damage-response-biomarkers-preclinical-oncology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/DNA-damage-response-biomarkers-preclinical-ongology-feature-e1744811293329.png\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/DNA-damage-response-biomarkers-preclinical-ongology-feature-e1744811293329.png\",\"width\":888,\"height\":628,\"caption\":\"Sygnature Discovery poster graphic showing DNA damage response biomarker analysis in a preclinical A549 model combining AZD7648 and radiotherapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/poster\\\/dna-damage-response-biomarkers-preclinical-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Early biomarker dynamics are associated with treatment efficacy in a preclinical model of radiotherapy combines with a DNA damage response agent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"name\":\"Sygnature Discovery\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\"},\"alternateName\":\"Sygnature\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#organization\",\"name\":\"Sygnature Discovery\",\"alternateName\":\"Sygnature\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Logo.svg\",\"width\":1,\"height\":1,\"caption\":\"Sygnature Discovery\"},\"image\":{\"@id\":\"https:\\\/\\\/www.sygnaturediscovery.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.youtube.com\\\/@sygnature.discovery\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/sygnature-discovery\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DNA Damage Response Biomarkers in Preclinical Oncology","description":"New A549 data showing DDR inhibition with radiotherapy improves in vivo efficacy, with biomarker and transcriptomic profiling of the response. Learn more.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/dna-damage-response-biomarkers-preclinical-oncology\/","og_locale":"fr_CA","og_type":"article","og_title":"DNA Damage Response Biomarkers in Preclinical Oncology","og_description":"New A549 data showing DDR inhibition with radiotherapy improves in vivo efficacy, with biomarker and transcriptomic profiling of the response. Learn more.","og_url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/dna-damage-response-biomarkers-preclinical-oncology\/","og_site_name":"Sygnature","article_modified_time":"2026-01-22T14:17:38+00:00","og_image":[{"width":888,"height":628,"url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/DNA-damage-response-biomarkers-preclinical-ongology-feature-e1744811293329.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/dna-damage-response-biomarkers-preclinical-oncology\/","url":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/dna-damage-response-biomarkers-preclinical-oncology\/","name":"DNA Damage Response Biomarkers in Preclinical Oncology","isPartOf":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/dna-damage-response-biomarkers-preclinical-oncology\/#primaryimage"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/dna-damage-response-biomarkers-preclinical-oncology\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/DNA-damage-response-biomarkers-preclinical-ongology-feature-e1744811293329.png","datePublished":"2025-04-28T13:00:10+00:00","dateModified":"2026-01-22T14:17:38+00:00","description":"New A549 data showing DDR inhibition with radiotherapy improves in vivo efficacy, with biomarker and transcriptomic profiling of the response. Learn more.","breadcrumb":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/dna-damage-response-biomarkers-preclinical-oncology\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sygnaturediscovery.com\/fr\/poster\/dna-damage-response-biomarkers-preclinical-oncology\/"]}]},{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/dna-damage-response-biomarkers-preclinical-oncology\/#primaryimage","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/DNA-damage-response-biomarkers-preclinical-ongology-feature-e1744811293329.png","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/DNA-damage-response-biomarkers-preclinical-ongology-feature-e1744811293329.png","width":888,"height":628,"caption":"Sygnature Discovery poster graphic showing DNA damage response biomarker analysis in a preclinical A549 model combining AZD7648 and radiotherapy"},{"@type":"BreadcrumbList","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/poster\/dna-damage-response-biomarkers-preclinical-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sygnaturediscovery.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Early biomarker dynamics are associated with treatment efficacy in a preclinical model of radiotherapy combines with a DNA damage response agent"}]},{"@type":"WebSite","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#website","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","name":"Sygnature Discovery","description":"","publisher":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization"},"alternateName":"Sygnature","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sygnaturediscovery.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#organization","name":"Sygnature Discovery","alternateName":"Sygnature","url":"https:\/\/www.sygnaturediscovery.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","contentUrl":"https:\/\/www.sygnaturediscovery.com\/wp-content\/uploads\/2025\/11\/Logo.svg","width":1,"height":1,"caption":"Sygnature Discovery"},"image":{"@id":"https:\/\/www.sygnaturediscovery.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.youtube.com\/@sygnature.discovery","https:\/\/www.linkedin.com\/company\/sygnature-discovery\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/4144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster"}],"about":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/types\/poster"}],"version-history":[{"count":0,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/poster\/4144\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media\/2883"}],"wp:attachment":[{"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/media?parent=4144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sygnaturediscovery.com\/fr\/wp-json\/wp\/v2\/category?post=4144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}